Allergy Therapeutics (AGY)

 

AGY Share PerformanceMore

52 week high31.00 13/04/17
52 week low17.25 26/09/16
52 week change 1.75 (7.45%)
4 week volume6,371,196 31/05/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Allergy Therapeutics hosts satellite symposium at EAACI

Allergy Therapeutics hosted a satellite symposium at the 36th annual congress of the European Academy of Allergy and C...

Satellite Symposium at EAACI 2017

RNS Number: 3866I Allergy Therapeutics PLC 19 June 2017 Al l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he " Group " ) Allergy Therapeutics hosts satellite symposium at EAACI 2017 ~ World-leading experts discuss allergy immunotherapies ~ Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialisi...

Directorate changes

RNS Number: 2053H Allergy Therapeutics PLC 06 June 2017 Al l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he " Group " ) Directorate changes 6 June 2017 Allergy Therapeutics (AIM:AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces the appointment of Dr Tunde Otulana to its Board of ...

Holding(s) in Company

RNS Number: 0263H Allergy Therapeutics PLC 02 June 2017 For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Allergy Therapeutics PLC 2 Reason for the notification ...

Issue of Equity

RNS Number: 3752C Allergy Therapeutics PLC 13 April 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Issue of equity in respect of the exercise of warrants and options 13 April 2017 Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces the issue and allotment ofa total n...

Hardman Research: Development across portfolio

RNS Number: 5821B Allergy Therapeutics PLC 05 April 2017 Hardman Research: Progressive development across portfolio Progressive development across portfolio - AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in EU only on a 'Named Patient' basis. Tr...

Broker Forecast - Numis issues a broker note on Allergy Therapeutics PLC

Numis today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and raised its price target to 4...

Interim Results for six months ended 31 Dec 2016

RNS Number: 8178A Allergy Therapeutics PLC 29 March 2017 Manuel Llobet, Chief Executive Officer, and Nick Wykeman, Finance Director, will host a meeting and call for analysts to provide an update on the Group, followed by a Q&A session, at 0900 BST today. Dial-in details are: +44 (0) 1452 555566. Conference ID: 75062637. Allergy Therapeutics plc ("Allergy Th...

Fundamental DataMore

EPS-2.29
Dividend yield0 %

Equity Research (AGY)

hardman & co
Allergy Therapeutics plc
06/04/2017
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in EU only on a ‘Named Patient’...
Allergy Therapeutics plc
15/11/2016
InnovaDerma* (IDP.L) 107.5p £10.98m Strong news flow this week from the main market listed  UK developer of 'at-home' and clinically proven treatments for hair loss, hair care, self-...
hardman & co
Allergy Therapeutics plc
26/09/2016
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in Europe only on a ‘Named...

Latest discussion posts More

  • FTWeekend

    Small Cap Focus Pharmaceuticals (Sarah Neville) 'From gene-editing to remedies for potentially fatal allergies, a cohort of biotechs is making scientific leaps that could ...
    26-Jun-2017
    jres
  • Read between the lines

    RNS - 19.06.2107 Manuel Llobet, Chief Executive Officer, commented: "We are delighted with our progress in developing the next generation of allergen immunotherapy products. ...
    21-Jun-2017
    Baffler
  • Malaria

    This AGY sponsored research from Bencard Adjuvant Systems (a division of Allergy Therapeutics UK) makes for interesting ...
    17-May-2017
    Totally Wired

Users' HoldingsMore

Users who hold Allergy Therapeutics also hold..
LLOYDS GRP.24%
BP20%
NATIONAL GRID18%
SIRIUS MINERALS18%
VODAFONE GRP.16%

Codes & Symbols

ISINGB00B02LCQ05
SymbolsAGY, LSE:AGY, AGY.L, AGY:LN, LON:AGY, XLON:AGY